PURPOSE: Exportin-1 (XPO1, CRM1) mediates the nuclear export of several key growth regulatory and tumor suppressor proteins. Cancer cells often overexpress XPO1 resulting in cytoplasmic mislocalization and aberrant activity of its target proteins. Orally bioavailable selective inhibitors of nuclear export (SINE) that irreversibly bind to and inhibit the function of XPO1 have been recently developed. The aim of this study was to investigate the efficacy of the clinical staged, orally available, SINE compound, KPT-330 in hepatocellular carcinoma (HCC). METHODS: In silico, meta-analysis showed that XPO1 is overexpressed in HCC. Six HCC cell lines were treated with KPT-330, and cell proliferation and expression of cell growth regulators were examined by cell proliferation assays and Western blot analysis, respectively. The in vivo anti-cancer activity of KPT-330 was examined in a HCC xenograft murine model. RESULTS: KPT-330 reduced the viability of HCC cell lines in vitro and this anti-proliferative effect was associated with cell cycle arrest and induction of apoptosis. The expression of the pro-apoptotic protein PUMA was markedly up-regulated by KPT-330. In addition, SINE treatment increased the expression of the tumor suppressor proteins p53 and p27, while it reduced the expression of HCC promoting proteins, c-Myc and c-Met. XPO1 levels itself were also down-regulated following KPT-330 treatment. Finally, a HCC xenograft murine model showed that treatment of mice with oral KPT-330 significantly inhibited tumor growth with little evidence of toxicity. CONCLUSION: Our results suggest that SINE compounds, such as KPT-330, are promising novel drugs for the targeted therapy of HCC.
PURPOSE:Exportin-1 (XPO1, CRM1) mediates the nuclear export of several key growth regulatory and tumor suppressor proteins. Cancer cells often overexpress XPO1 resulting in cytoplasmic mislocalization and aberrant activity of its target proteins. Orally bioavailable selective inhibitors of nuclear export (SINE) that irreversibly bind to and inhibit the function of XPO1 have been recently developed. The aim of this study was to investigate the efficacy of the clinical staged, orally available, SINE compound, KPT-330 in hepatocellular carcinoma (HCC). METHODS: In silico, meta-analysis showed that XPO1 is overexpressed in HCC. Six HCC cell lines were treated with KPT-330, and cell proliferation and expression of cell growth regulators were examined by cell proliferation assays and Western blot analysis, respectively. The in vivo anti-cancer activity of KPT-330 was examined in a HCC xenograft murine model. RESULTS:KPT-330 reduced the viability of HCC cell lines in vitro and this anti-proliferative effect was associated with cell cycle arrest and induction of apoptosis. The expression of the pro-apoptotic protein PUMA was markedly up-regulated by KPT-330. In addition, SINE treatment increased the expression of the tumor suppressor proteins p53 and p27, while it reduced the expression of HCC promoting proteins, c-Myc and c-Met. XPO1 levels itself were also down-regulated following KPT-330 treatment. Finally, a HCC xenograft murine model showed that treatment of mice with oral KPT-330 significantly inhibited tumor growth with little evidence of toxicity. CONCLUSION: Our results suggest that SINE compounds, such as KPT-330, are promising novel drugs for the targeted therapy of HCC.
Authors: N Kudo; N Matsumori; H Taoka; D Fujiwara; E P Schreiner; B Wolff; M Yoshida; S Horinouchi Journal: Proc Natl Acad Sci U S A Date: 1999-08-03 Impact factor: 11.205
Authors: Y-T Tai; Y Landesman; C Acharya; Y Calle; M Y Zhong; M Cea; D Tannenbaum; A Cagnetta; M Reagan; A A Munshi; W Senapedis; J R Saint-Martin; T Kashyap; S Shacham; M Kauffman; Y Gu; L Wu; I Ghobrial; F Zhan; A L Kung; S A Schey; P Richardson; N C Munshi; K C Anderson Journal: Leukemia Date: 2013-04-16 Impact factor: 11.528
Authors: Pauline J van der Watt; Christopher P Maske; Denver T Hendricks; M Iqbal Parker; Lynette Denny; Dhirendra Govender; Michael J Birrer; Virna D Leaner Journal: Int J Cancer Date: 2009-04-15 Impact factor: 7.396
Authors: Dongqing Yan; Anthony D Pomicter; Srinivas Tantravahi; Clinton C Mason; Anna V Senina; Jonathan M Ahmann; Qiang Wang; Hein Than; Ami B Patel; William L Heaton; Anna M Eiring; Phillip M Clair; Kevin C Gantz; Hannah M Redwine; Sabina I Swierczek; Brayden J Halverson; Erkan Baloglu; Sharon Shacham; Jamshid S Khorashad; Todd W Kelley; Mohamed E Salama; Rodney R Miles; Kenneth M Boucher; Josef T Prchal; Thomas O'Hare; Michael W Deininger Journal: Clin Cancer Res Date: 2018-12-18 Impact factor: 12.531
Authors: Patricia A Jorquera; Cynthia Mathew; Reena Ghildyal; Jennifer Pickens; Colin Williams; Jasmina M Luczo; Sharon Tamir; Ralph A Tripp Journal: J Virol Date: 2019-02-05 Impact factor: 5.103
Authors: Jennifer R Landes; Stephen A Moore; Brooke R Bartley; Hung Q Doan; Peter L Rady; Stephen K Tyring Journal: J Cancer Res Clin Oncol Date: 2022-08-08 Impact factor: 4.322
Authors: Joel G Turner; Yan Cui; Alexis A Bauer; Jana L Dawson; Juan A Gomez; Jongphil Kim; Christopher L Cubitt; Taiga Nishihori; William S Dalton; Daniel M Sullivan Journal: Cancer Res Date: 2020-10-06 Impact factor: 12.701
Authors: Melissa A Fischer; Sharon Y Friedlander; Maria P Arrate; Hua Chang; Agnieszka E Gorska; Londa D Fuller; Haley E Ramsey; Trinayan Kashyap; Christian Argueta; Sophie Debler; Michael Byrne; Matthew T Villaume; Aaron C Shaver; William Senapedis; Yosef Landesman; Erkan Baloglu; Sharon Shacham; Michael R Savona Journal: Blood Adv Date: 2020-02-11